# Bristol Myers Squibb's oral drug mezigdomide is making waves in the medical community.

*biotech · news · 2026-05-30 · Devdiscourse*

## Key points

- Mezigdomide reduced the risk of multiple myeloma progression or death by 52% in trials.
- CVS Health has restored insurance coverage for Eli Lilly's Zepbound and newly approved pill Foundayo.
- CVS's coverage decision resulted from price negotiations involving Novo Nordisk, its direct competitor.
- A U.S. proposal for an Ebola quarantine facility in Kenya was halted by local judicial action.

Bristol Myers Squibb's innovative oral drug mezigdomide is making waves in the medical community. In a late-stage trial, the drug effectively delayed the progression of multiple myeloma in patients unresponsive to other treatments, cutting the risk of disease progression or death by 52%. CVS Health reinstated coverage for Eli Lilly's obesity drug Zepbound along with its newly approved obesity pill, Foundayo. This decision comes after negotiations regarding pricing with competing drugmaker Novo Nordisk, highlighting the strategic battles within the pharmaceutical industry. In Kenya, a U.S. plan to establish an Ebola quarantine facility met judicial roadblocks, questioning its potential public health risks. The suspension reflects ongoing global concerns about Ebola's spread and the measures being undertaken to control it. (With inputs from agencies.)

**Companies:** Bristol Myers Squibb, CVS Health, Eli Lilly, Novo Nordisk
**Countries:** United States, Kenya

[Read the full story on Devdiscourse](https://www.devdiscourse.com/article/health/3926672-myeloma-drug-shows-promise-cvs-backs-obesity-treatments-kenya-ebola-quarantine-raises-concerns)

---

Canonical: https://newsio.io/n/a84985a0-48f6-4f08-88db-200b76e9852f/bristol-myers-squibbs-oral-drug-mezigdomide-is-making-waves-in-the-medical-commu
Summarized by Newsio from Devdiscourse. https://newsio.io/how-it-works